Multispecific Antibody Targeting BCMA and CD3 for Autoimmune Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune disorders, such as ANCA-associated vasculitis, are not always effective in inducing or maintaining remission and can have undesirable side effects, highlighting a need for more effective therapies.
Innovation Solution
The use of multispecific (bispecific) antibodies that bind to BCMA and an antigen promoting T cell activation, specifically CD3, to target and manage autoimmune disorders by selectively depleting autoreactive B lineage cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for autoimmune disorders, then some therapeutic effect is achieved, but effectiveness in inducing and maintaining remission is insufficient and undesirable side effects occur
Solution Approach 1:
The treatment approach is segmented into two distinct mechanisms: BCMA binding for selective B cell depletion and CD3 binding for T cell activation. This segmentation allows each component to perform its specific function optimally while working synergistically to achieve better remission outcomes with reduced side effects compared to single-mechanism therapies
Solution Approach 2:
The patent employs a composite antibody structure that integrates both BCMA and CD3 binding capabilities in a single molecular entity. This composite design enables simultaneous engagement of B cells and T cells, creating a synergistic therapeutic effect that overcomes the limitations of conventional monotherapy approaches
2Duration of action of stationary object
If traditional treatments are administered, then some disease control is achieved, but the duration of remission is limited
Solution Approach 1:
The multispecific antibody performs preliminary depletion of autoreactive B cells and plasmablasts before disease relapse can occur. By proactively eliminating the pathogenic cell population and activating T cell surveillance, the treatment establishes a protective state that extends remission duration and prevents recurrence
Solution Approach 2:
The CD3 binding component creates a feedback mechanism where activated T cells continuously monitor and respond to any resurgence of autoreactive B cells. This real-time immune surveillance provides dynamic control that maintains long-term remission by quickly eliminating emerging pathogenic cells
Data Source
AI summary
The present invention relates to the treatment or management of autoimmune disorders, such as autoimmune disorders caused by autoreactive B lineage cells, e.g. anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).